Search Results for: HCV

December 20, 2016December 20, 2016

Hepatitis C Therapy Sovaldi Can Adversely Interact with HIV Therapy Viread, Study Says

Hepatitis C, News

The hepatitis C drug Sovaldi (sofosbuvir) can adversely interact with the human immunodeficiency virus (HIV) drug Viread (tenofovir disoproxil), according to recent findings. Both drugs are manufactured and commercialized by Gilead ... Read more

December 6, 2016December 6, 2016

European Medical Officials Join Chorus of Warnings About Risk of Hep B Reactivation with Direct-Acting Antiviral Drugs Used for Hep C

Hepatitis B, Hepatitis C, News

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has confirmed that patients being treated with certain direct-acting antiviral (DAA) drugs for hepatitis C virus (HCV) infection ... Read more

November 29, 2016November 29, 2016

Gilead Sciences Canada Recognized for Developing Harvoni as Hepatitis C Therapy

Hepatitis C, News

Gilead Sciences Canada has been awarded this year’s Prix Galien Canada–Innovative Product Award for the development of Harvoni (ledipasvir/sofosbuvir), a once-daily combination pill for the treatment of chronic genotype 1 hepatitis ... Read more

November 8, 2016November 8, 2016

Promising Phase 1 Data Reported for Chronic Hepatitis C Investigational Therapy

Hepatitis C, News

Phase 1 clinical trial results show that CoCrystal Pharma’s CC-31244, a potential new therapy for hepatitis C virus (HCV) infections, meets the criteria to qualify for further testing. The randomized, ... Read more

October 25, 2016October 25, 2016

Combo Anti-Viral Treatment for Chronic Hepatitis C Shows Efficacy in Phase 3 Studies

Hepatitis C, News

Top-line results from four global Phase 3 clinical studies (POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4), led by Gilead Sciences, showed that the combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) — inhibitors of viral activity — can ... Read more

October 13, 2016October 13, 2016

Hep C Halted from Hijacking Metabolic Process Points to New Treatment Strategy

Hepatitis C, News

Preventing virus-triggered changes in human metabolic processes might become a future way to stymie viral infections, according to a recent study by an international group of scientists at the Hebrew University of Jerusalem. ... Read more

October 6, 2016October 6, 2016

FDA Warns Risk of Hepatitis B Reactivating with Certain Antiviral Drugs for Hepatitis C

Hepatitis B, Hepatitis C, News

Earlier this week, the U.S. Food and Drug Administration (FDA) warned about serious risks for patients infected with the hepatitis B virus (HBV) and who are being treated with certain direct-acting antiviral ... Read more

September 27, 2016October 4, 2016

NICE Approves Epclusa to Treat More Genotypes of Hepatitis C

Hepatitis C, News

The U.K. National Health Service’s (NHS) National Institute for Health and Care Excellence (NICE) recently published a new draft guidance recommending Epclusa (sofosbuvir-velpatasvir), an anti-viral drug that offers patients with chronic ... Read more

July 5, 2016July 5, 2016

MassHealth Expands Access to Hepatitis C Therapies Like Harvoni

Hepatitis C, News

Leaders in Massachusetts recently took steps to ensure that all members of MassHealth, the state’s health insurance program for low- and moderate-income residents, have access to medications to treat hepatitis C. Following months of negotiations, MassHealth ... Read more

June 30, 2016June 30, 2016

Epclusa for All Genotypes of Hepatitis C Virus Approved by FDA

Hepatitis C, News

The U.S. Food and Drug Administration (FDA) approved Epclusa for the treatment of patients with chronic hepatitis C virus (HCV) infection. Epclusa can be used as a monotherapy for patients without cirrhosis (late ... Read more